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New approaches to generate effective anticancer responses by either inducing immune responses or inhibiting
immunosuppression are under development to improve efficacy in patients. On March 4-5th, 2014, a symposium was
held in Pamplona, Spain, to report the new strategies showing preclinical and clinical results regarding translational
research efforts on the topic. Participants interacted through oral presentations of 15 speakers and further discussions
on topics that included novel therapeutic agents for cancer immunotherapy, viral vectors and interferon-based
approaches, experimental tumor imaging and immunostimulatory monoclonal antibodies. Promising agents to target
cancer cells and therapeutic approaches that are under translation from bench to patients were presented.Report
The many and excellent results of cancer immunotherapy
strategies are dazzling in the eyes of clinical oncologists.
Immunomodulation and adoptive T cell therapies are tak-
ing the limelight from years of obscure and busy basic,
translational and clinical research. The meeting that we
report was aimed to be most translational, mixing to-
gether presentations on new agents, mechanisms of ac-
tion, clinical results and new problems from bench to bed
(Table 1). We need researchers to team in asking and an-
swering the questions which will let us make the most of
the ongoing immunotherapy revolution. As Walt Disney
said once: “Let’s never forget that everything started with a
mouse”. Indeed, most of the talks in this meeting started
with mouse data and many of them finished with human
results. This significant trend is telling us that translation
is paying off.Viral vectors and interferon-based approaches in cancer
immunotherapy
In the opening keynote lecture of the symposium, Guido
Kroemer (Institut Gustave Roussy, France) described the* Correspondence: jquetglas@unav.es
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unless otherwise stated.immune-dependent effects of chemotherapy. Physiological
cell death, which occurs as a continuous byproduct of cel-
lular turnover, is non-immunogenic or even tolerogenic,
thereby avoiding autoimmunity. However, cancer cell
death elicited by radiotherapy and some chemotherapeutic
agents such as anthracyclines and oxaliplatin can be im-
munogenic. Immunogenic cell death is characterized by
the early cell surface exposure of calreticulin, which deter-
mines the uptake of tumor antigens by dendritic cells
(DC). The late release of the protein high mobility group
box 1 (HMGB1), which acts on toll-like receptor 4
(TLR4), is required for the presentation of antigens from
dying tumor cells. In addition, the autophagy-dependent
release of ATP from dying cells causes the purinergic
P2Y2-dependent chemotaxis of cells from the myeloid
lineage and the P2RX7-dependent activation of the
NLRP3 inflammasome in DC [1]. Kroemer postulated that
the immune system determines the long-term success of
anti-cancer therapies, and that this immune response is
dictated by immunogenic tumor cell death. Indeed, he
demonstrated results from the immunohistochemical
characterization of human breast cancer specimens sug-
gesting that signs of immunogenic cell death do have a
major prognostic impact.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 List of the speakers, affiliations, titles of the talks and their corresponding section in the report
Speaker Affiliation Talk title Section
Guido
Kroemer




Center for Applied Medical Research (CIMA),
Spain.




Center for Applied Medical Research (CIMA),
Spain.
New roles for the Type I IFN system in cancer immunology.
David Escors Navarrabiomed, Spain. Ex vivo differentiation of cancer-specific myeloid-derived suppressor cells and their
use in cancer immunotherapy.
David Sancho Centro Nacional de Investigaciones
Cardiovasculares Carlos III (CNIC), Spain.
A dendritic cell receptor for damaged self is crucial for anti-viral immunity.
Bettina
Weigelin
Radboud University Nijmegen, The Netherlands. Dynamic imaging reveals serial killing of cancer cells by CTL: New strategies to
overcome tumor resistance niches.




Institut Pasteur, France. In vivo imaging of immune tumor rejections.
Ignacio
Melero
Center for Applied Medical Research (CIMA),
Spain.
Making the most of CD137 and IL-15 for cancer immunotherapy. Immunostimulatory monoclonal antibodies.
Bruno Paiva Center for Applied Medical Research (CIMA),
Spain.




National Tumor Institute Fondazione G. Pascale,
Italy.
Biomarkers for check point blockade.
Kohrt
Holbrook
Stanford University, USA. Stimulation of Natural Killer Cells with an Anti-CD137 Antibody Enhances the
Efficacy of Trastuzumab, Cetuximab & Rituximab.
Noelia
Casares
Center for Applied Medical Research (CIMA),
Spain.




Spanish National Cancer Research Centre (CNIO),
Spain.
New animal models for gene discovery and drug screening.
Fernando
Pastor
Center for Applied Medical Research (CIMA),
Spain.
CD137 and CD28 agonist aptamers.
Luis Álvarez-
Vallina
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approach to treat tumors because of their ability for both
killing cancer cells and awakening the immune system to
attack the tumor. Cristian Smerdou (Center for Applied
Medical Research (CIMA), Spain) presented extensive
work with a Semliki Forest virus (SFV) replicon express-
ing interleukin-12 (IL-12; SFV-IL-12). In subcutaneous
transplanted tumor models in mice, SFV-IL-12 had shown
a curing efficacy greater than 90%. In contrast, its efficacy
was reduced in spontaneous hepatocellular carcinoma
(HCC) models. Smerdou showed that it is possible to
increase the SFV-IL-12 effector response by combining
the vector with an agonist mAb for CD137. Anti-CD137
synergized powerfully with the viral vector, promoting a
great expansion of functional CD8+ T cells, while redu-
cing dramatically SFV neutralizing antibodies, opening a
door to multiple reinjections of the vector [2].
IFNα is a pleiotropic cytokine that plays an important
role in the generation of immune responses. Sandra
Hervás-Stubbs (Center for Applied Medical Research
(CIMA), Spain) focused her talk in two critical topics: the
contribution of IFNα for naïve CD8+ T cell priming and
the importance of host type I IFN response induced by
viral vectors carrying therapeutic transgenes used in ex-
perimental cancer treatment. Hervás-Stubbs showed how
the presence of IFNα during CD8+ T cell priming in-
creased responsiveness to homeostatic cytokines and re-
call antigens, providing a method to more efficiently
generate human cytotoxic T lymphocytes (CTLs) from the
naïve T-cell repertoire [3,4]. Intratumor replication of SFV
genomes generates large quantities of ssRNA and dsRNA
intermediate forms that can be sensed by host cells, lead-
ing to IFN-I expression. When IFN-α signaling was
blocked (either genetically or by using neutralizing anti-
body), SFV-IL-12 anti-tumor efficacy mediated by CTLs
was completely lost. These results emphasize the fact that
type I IFN signaling could be crucial for the clinical bene-
fit with viral vectors delivering therapeutic genes and cyto-
pathic virotherapy (manuscript in preparation).
David Escors from Navarrabiomed, in Spain, presented
vaccine strategies using DCs as therapeutic agents. Silen-
cing of PD-L1 in DCs during lymphocyte priming induced
a hyperactivation of T cells, mounting a faster response
against tumors, but without any improvement of the final
outcome of mice. Next, Escors constructed a panel of len-
tivectors expressing a cytokine gene, a shRNA against PD-
L1 and a tumor antigen. A lentivector expressing IL-12
and TRP-1 as tumor antigen offered the best results fol-
lowing intratumoral delivery. Escors concluded that it was
more important to inhibit PD-L1 expression and express
IL12 both in immune and non-immune cells (e.g. in
tumor cells). A novel method of culture/differentiation of
myeloid derived suppressor cells (MDSCs) was presented
and MDSCs transduced with the lentivector codifying forIL-12 plus PD-L1 shRNA and TRP-1 became efficient
antigen presenting cells (APCs), leading to in vitro IFNγ
expression by CD8+ T cells (manuscript in preparation).
David Sancho (Centro Nacional de Investigaciones
Cardiovasculares Carlos III (CNIC), Spain) showed data
on the role of the C-type lectin DNGR-1 (Clec9a) in the
generation of immunity against viral infections. DNGR-1
is expressed selectively in the main subset of DC which
mediates crosspriming. DNGR-1 expression on DCs and
sensing of F-actin in dead cell debris was shown to be
crucial for the generation of immunity against dead-cell
associated antigens. Sancho`s recent work in a vaccinia
virus model that showed the crucial contribution of
DNGR-1 is at the level of cross-presentation of dead-cell
associated antigen. Current work is focusing on the ana-
lysis of the secondary response to vaccinia vaccines,
which is also impaired in the absence of DNGR-1. These
results suggest that tissue damage sensed via DNGR-1
contributes to the efficacy of vaccines by means facilitat-
ing antigen cross-presentation [5].
Experimental tumor imaging in immunotherapy
Two talks of the symposium were focused on the most
novel in vivo imaging techniques to give light to the mecha-
nisms of immunotherapy at cellular and tissue level. In this
regard, Bettina Weigelin (Radboud University Nijmegen,
The Netherlands) presented a model to image CTLs
in vitro and in vivo. Time-lapse recordings obtained by dy-
namic imaging of 3D collagen matrices containing tumor
cells and antigen-specific CTL allowed to dissect the differ-
ent phases of CTL-mediated killing. The approach helped
to identify a CTL crowd-based, serial killing mechanism
dependent on sequential CTL-tumor cell interactions and
the accumulation of sub-lethal hits to overcome melanoma
cell resistance to CTL mediated apoptosis. The cooperation
between multiple CTL acted as a compensation mechan-
ism to maintain CTL killing efficiency if individual CTL
contacts were weakened by factors of the tumor micro-
environment. Intravital multiphoton microscopy (IVM), a
powerful method for the exploration of biological processes
in the physiological tissue context, enables monitoring cell
migration and tumor dynamics. Spectacular movies with
this technique showed that tissue interfaces guided tumor
cell invasion and promoted the formation of collective,
finger-like tumor cell strands infiltrating the healthy tissue.
The same pro-invasive tissue tracks enhanced the fre-
quency of OT1 CTL interactions with B16 melanoma cells
causing preferential targeting of invading tumor cells by
CTL. Furthermore, imaging of adoptive OT-1 CTL therapy
and CD137 co-stimulation with administered mAb demon-
strated that the combined therapy approach prolonged the
cytotoxic phase of CTL resulting in a more focused and ef-
ficacious CTL effector phenotype in vivo (manuscript in
preparation).
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of in vivo imaging of NK cytotoxic mechanisms in solid
tumors and the effect of anti-tumor antibody immuno-
therapy. Dynamic In Situ Cytometry (DISC) combines
IVM with flow cytometry-like multiparametric pheno-
typic analyses. Bousso demonstrated that NK cells inter-
acted more transiently with their targets than CTL and
NK tumor infiltration was less constrained by tumor cell
density. The distinct dynamics of CTL and NK cells dur-
ing killing reflected difference in calcium signaling upon
interaction with their target. The studies of NK cell–me-
diated lysis indicated that NKG2D engagement promotes
degranulation whereas FcR- signals play a critical role in
NK-to-target contact stability [6]. Bousso also presented
results of the characterization of in vivo mechanisms of
anti-CD20 antibody therapy in B cell malignancies ob-
tained IVM techniques. Bousso’s group studies indicate
that the liver plays a central role in anti-CD20-mediated
B cell depletion, and such depletion is contingent on B
cell circulation. Anti-CD20 therapy induces circulating B
cells to arrest in liver. Effectiveness of treatment is critically
dependent on Kupffer cells (KC) [7]. Moreover, intravital
imaging of Csfr1gfp/+Cd19cre/+Rosa26RFP/+Eμ-myc+/−
mice developing spontaneous lymphomas reveals engulf-
ment of tumor B cells by KC in liver sinusoids upon anti-
CD20 mAb injection.
Immunostimulatory monoclonal antibodies
CD137 (4-1BB) is a costimulatory receptor expressed on
various immune system cells upon activation, including
T and NK cells, and also on tumor endothelial cells.
CD137 activation renders multiple effects such as: apop-
tosis resistance, proliferation, and gains in effector func-
tions, antigen presentation and cytokine production.
Little is known about its intimate mechanism of signal
transduction from this. Ignacio Melero (Center for Ap-
plied Medical Research (CIMA), Spain) showed how
CD137 activation leads to a TRAF-2 recruitment to the
receptor and the formation of K63 polyubiquitin chains
attached to TRAF2 and other substrates. K63 ubiquitin-
ligase activity elicited CD137 crosslinking was crucial for
downstream activation of NF-κB. Interestingly CD137 is
internalized to endosomes following crosslinking but
keeps its signaling function from such CD137 endosomes.
Importantly, signaling is regulated by the deubiquitinases
CYLD and A20. Of note, TRAF2 dominant-negative
transgenic mice exhibited a delay in tumor rejection when
treated with anti-CD137 mAb (manuscript in prepar-
ation). Melero’s talk continued with immunotherapy in
a mouse model of spontaneous c-myc/OVA hepatocellular
carcinoma (HCC). A triple mAb combination (anti-
CD137 + anti-PD-L1 + anti-OX40, called Combo3)
extended survival of the mice and this was even more effi-
cacious when further combined to adoptive T cell therapy[8]. Melero also presented results about a new triple fu-
sion protein constituted for Sushi domain of IL-15Rα, IL-
15 and Apolipoprotein A-I. This chimeric protein had an
extended half-life and a superior antimetastatic efficacy
compared to other forms of IL-15 in tumor-bearing
mice [9].
Bruno Paiva (Center for Applied Medical Research
(CIMA), Spain) reviewed the spectrum of monoclonal
gammopathies, including the malignant stage of multiple
myeloma (MM). Despite significant therapeutic efforts
MM remain an incurable disease and therefore several
drugs with new mechanisms of action, including cellular
immunotherapeutic strategies, are being developed to
improve anti-myeloma immunity. MAb-based therapies
function by ADCC or CDC by NK or T cells. On
this subject, elotuzumab mediates ADCC in preclinical
models. Importantly, ADCC activity of elotuzumab
against MM cells is enhanced by lenalidomide, providing
the framework for an ongoing phase III combination
trial. Integration of novel agents into the transplant and
non-transplant settings has significantly prolonged
patients’ survival; persistent minimal residual disease
(MRD) is often observed and translates into significantly
inferior PFS and OS. In this regard, Paiva presented results
suggesting that this small chemoresistant clones (MRD
cells) might show unique genomic and phenotypic charac-
teristics, including higher PD-L1 expression. Conversely,
MM patients with long-term disease control have a con-
stellation of unique immune changes favoring both im-
mune cytotoxicity and recovery of B-cell production and
homing, suggesting improved immune surveillance. In
summary, these data will hopefully drive rational develop-
ment of immunotherapeutic strategies for MM patients.
Immunotherapy for cancer treatment has won power-
ful allies in the recent years with the development of
immunostimulatory mAbs. Especially relevant is the
case of ipilimumab, an anti-CTL-associated antigen 4
(CTLA-4) antibody that blocks the inhibitory activities
of this molecule expressed by activated T-lymphocytes
and regulatory T cells. This therapeutic agent is the first
ever exhibiting a survival improvement in metastatic
melanoma. However, the finding of a predictive bio-
marker to identify patients who might benefit from ipili-
mumab treatment remains as a major unmet goal, as
was claimed by Paolo Ascierto (National Tumor Insti-
tute Fondazione G. Pascale, Italy). The search for bio-
markers has focused mainly in blood and tumor tissues
[10]. The search for biomarkers has focused mainly in
blood and tumor tissues. Among other candidates, abso-
lute lymphocyte count (ALC), tumoral immuno infiltrate
evaluation (TIL, FoxP3, IDO), upregulation of inducible
costimulator (ICOS) molecule in T cells or an elevation
of circulating Ki67+EOMES+CD8+ T cells stand out. All
of them correlate with clinical benefit and overall
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spective studies. Besides, infiltration of M1 or M2 macro-
phages can influence the outcome of this treatment.
CD124 and CD206 are markers for M2 phenotype, and
their presence correlates with disease recurrence in pre-
clinical model. Ascierto also made comments about new
possible biomarkers in the form of genetic polymorphisms
in CTLA-4 gene. It has been seen that responders to ipili-
mumab treatment share certain polymorphisms and non-
responders do not. This preliminary finding represents a
new exciting way to predict success with ipilimumab treat-
ment that needs to be explored more deeply.
The study of the effects exerted by immunomodula-
tory mAbs has often been focused on T cells, but their
molecular targets can usually be also found on other
leukocyte subsets such as NK cells. These lymphocytes
can mediate their cytotoxic effects on target cells directly
or by means of antibody-dependent cell-mediated cyto-
toxicity (ADCC). This kind of induced cell death is the
basis of the therapeutic effects of anticancer antibodies
rituximab (anti-CD20, used against lymphomas), trastu-
zumab (anti-HER2, breast cancer) and cetuximab (anti-
EGFR, head and neck cancers). Holbrook Kohrt, from
Stanford University (USA), presented interesting work
from bench to bedside, starting from the observation
that the three antibodies enumerated above induced the
expression of CD137 on NK cells, only in the presence
of the corresponding antigen-positive tumor. Kohrt and
Levy moved first to in vitro experiments and checked
that the addition of anti-CD137 augmented ADCC me-
diated by NK cells. These results were further confirmed
in nude mice bearing tumors from human origin [11,12].
Results in patients show a heterogeneous induction of
CD137 on NK cells after treatment with antitumor
mAbs. Kohrt identified five factors contributing to het-
erogeneity: tumor histology, time post-antitumor mAb
therapy, tumor burden, span of prior antitumor mAb
treatment and FcγRIIIa allelic polymorphism. Regarding
the last factor, those alleles with less affinity for IgG Fc
induced weaker CD137 expression on the NK cells.
Holbrook ended his talk showing promising preliminary
data of several new rituximab combinations, including a
phase I/II clinical trial combining rituximab with urelu-
mab (anti-CD137), a phase I/II clinical trial in combin-
ation with a humanized anti-PD-1 mAb, and preclinical
results in combination with anti-CD47 (“don’t eat me”
signal). The results obtained are very exciting and begin a
new era in immunotherapy targeting the innate immune
response.
Novel therapeutic agents for cancer immunotherapy
Tumors can counteract immune system surveillance by a
variety of mechanisms, including the subversive use of cyto-
kines and the exploitation of immunosupressor abilities ofcells such as Regulatory T cells (Tregs) and myeloid-
derived suppressor cells. Noelia Casares (Center for Ap-
plied Medical Research (CIMA), Spain) proposed strategies
to inhibit Foxp3, a master regulator of Tregs, through the
use of cell-penetrating peptide inhibitors. Two peptides
were obtained from different approaches: the first of them
(P60) using a phage-displayed random peptide library, the
other one (Foxp3-393) based on the crystal structure of
NFAT1:Foxp3:DNA complex. P60 inhibited murine and
human-derived Treg activity and in vivo administration im-
proved antitumor and antiviral immunotherapies [13].
Foxp3-393 was shown to function as a decoy peptide, dis-
rupting NFAT:Foxp3 interaction, resulting in Treg activity
reduction. On the contrary, this peptide resulted in func-
tional CD40L expression on T cells and enhanced produc-
tion of cytokines such as IL-2, IFN-γ or IL-17 in response
to TCR stimulation (manuscript in preparation).
Tumors exploit the lymphatic vasculature for regional
metastasis. Several cytokines and signaling receptors are
involved in lymphangiogenesis, like vascular endothelial
growth factor receptor 3 (VEGFR-3). Marisol Soengas
(Spanish National Cancer Research Centre (CNIO), Spain)
presented a VEGFR-3-GFP-Luciferase-reporter transgenic
mouse model for in vivo imaging of tumor-associated
lymphangiogenesis. This lymphatic vessel reporter mouse
was shown very useful to monitor new lymphatic vessels
associated to grafted or spontaneous tumors. For instance,
tumors induce VEGFR-3 in draining lymph nodes thereby
preconditioning a niche for eventual metastasis. Soengas’
group has identified BO-110 as a new pro-autophagy and
apoptosis inducer in melanoma cells. BO-110 consists of
synthetic long dsRNA nanocomplexes that can be sensed
by TLR3 and MDA-5, inducing autophagy and caspase ac-
tivation in melanoma cells, but not in normal melanocytes
[14,15]. BO-110 has been tested both in vitro and in vivo,
showing a potent antitumoral effect in different tumor
models, inhibiting metastasis and lymphatic vessels forma-
tion too. In addition, BO-110 exhibits several effects in
immune system cells including transition from M2 (protu-
morigenic) to M1 (antitumorigenic) macrophages. BO-
110 also induced PD-L1 expression in melanoma cells,
opening the door to combinations with monoclonal anti-
bodies against PD-1 or PD-L1.
Oligonucleotide-based aptamer ligands represent a prom-
ising alternative to monoclonal antibodies (mAb) as tools
to enhance immune responses and for counteracting im-
munosuppression. Fernando Pastor (Center for Applied
Medical Research (CIMA), Spain) presented three effective
approaches with aptamers in immunotherapy [16]. The first
one was based on interference with non-sense mediated
mRNA decay (NMD). siRNAs interfering with this cellular
system were conjugated to an oligonucleotide aptamer that
binds to prostate-specific membrane antigen (PSMA) for
tumor targeting. Knocking down NMD in tumor cells
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dons and aberrant proteins leading to tumor antigenicity.
Next, Pastor presented an anti-CD28 aptamer engineered
to function as an agonist as a strategy to potentiate antican-
cer immune responses. Administration in combination with
anti-idiotype vaccine increased survival in subcutaneous
A20 lymphoma-bearing mice. A third approach presented
was a 4-1BB aptamer ligand conjugated to a tumor-
targeting aptamer. Systemic administration of this chimeric
aptamer resulted in a tumor-specific immune response
against subcutaneous CT26 mouse models in a 4-1BB and
PSMA-dependent manner.
Luis Álvarez-Vallina (Hospital Universitario Puerta de
Hierro, Spain) updated new antibody platforms that are
emerging as very promising scaffolds for immunotherapy
and anti-angiogenesis. For these purposes the trimerbody
platform was presented [17,18]. Trimerbodies are composed
of single-chain variable fragments (scFv) connected though
flexible linkers to the N- and /or C-terminus of a collagen-
derived trimerization subdomain. Álvarez-Vallina disclosed
the results of anti-human carcinoembryonic antigen (CEA)
scFv-based N-trimerbody for tumor targeting and imaging.
Furthermore, Álvarez-Vallina exposed the effects of a
VEGF–blocking human single-domain antibody-mimetic
(VB-SDAM)-based N-terminal trimerbody on VEGF-
mediated endothelial cell proliferation and migration
in vitro. Trimerbodies offer multiple possibilities to gener-
ate multivalent and/or multispecific molecules precisely
engineered to meet specific target and requirements.Conclusion
The sessions were attended by about 130 participants. At
least 64 of them were aged under 30. Questions and conver-
sations indicated an excellent level among young profes-
sionals of immune-oncology including graduate students
and residents. The future is theirs and they will deliver the
promise of cancer immunotherapy as it is turning into suc-
cessful reality. A talented young female resident told one of
the authors during a coffee break: “This stuff seems to work,
but only sometimes. It looks quite difficult to predict in spite
of the beauty of the mechanisms. The field is surely full of
unknowns and unknown unknowns” (translated from the
original Spanish). She got it right, we think that this is a
great scientific conclusion, to summarize the presentations.
Pamplona (Spain) provided an attractive environment
for the meeting in which moderate doses of excellent
wines, good humor and the participation of young investi-
gators forecast the birth and consolidation of productive
collaborations which are already fostering translational re-
search efforts in cancer immunotherapy.
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